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ABSTRACT 
The pharmaceutical industry is currently one of the most dynamic among all industries. At present, it is striking with various compliance challenges 
like never before there is increased regulation, acquisitions, push toward harmonization and endemic in a Data Integrity (DI) concern. DI weakness 
is identified, either as a result of an audit or a regulatory inspection, companies with multiple sites should ensure that appropriate corrective and 
preventive actions are implemented across the organizations and appropriate notification to regulatory authorities should be made wherever 
applicable. The objective of the study carries the number of issues involved within data integrity in current GMP aspects, the root causes were 
addressed based on warning letters. This review intends to study the concept of data integrity holistically in all aspects, regulatory expectations and 
to evaluate the state of compliance and challenges that explore to suggest appropriate remedial and proactive measures to avoid DI issues. There 
were many challenges involved to overcome the issues, which are all about the one's handling by maintaining good documentation practice. The 
importance, strategies and recommendations were discussed to overcome from the repeated data integrity mistakes. 
This review was carried out by systematic searches of data integrity in relevant guidelines, published articles, reviews and abstracts in Google 
scholar, Pubmed, Science direct, Embase, Web of science, Cochrane database of systematic reviews of articles up to March 2020. The keywords used 
for gathering information were listed below. 
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INTRODUCTION 
Data integrity (DI) is the assurance of data records that are complete, 
accurate, intact, and maintained within the original circumstance, 
including their connectivity to relevant data records and focuses to 
prevent unwanted changes to the required information [1]. DI is much 
important for the management of a quality system in the 
pharmaceutical industry, which ensures that medicines are safe based 
on the evidence of data. Due to issues with DI, there was a 
considerable increase in enforcement actions taken by regulatory 
bodies [2]. With faster growth in the generics market, economical and 
regulations on pharmaceutical manufacturers is increasing nowadays. 
In recent years there has been a significant increase in the number and 
types of data integrity issues that have been cited in regulatory 
inspections [3]. The DI related cGMP violations have leads to several 
regulatory actions, including warning letters, import alerts and 
seizures. There were many uncovered serious cases on DI related 
problems. Companies often have DI issues, which are hazardous to the 
company's long-term prospects and a demoralizing effect on the 
company culture [4]. Managing data is challenging in the 
pharmaceutical industry, especially when a firm's growth was 
emerging on a volume of data at a rapid rate. Distrustful data quality 
can result in severe consequences for the responsible organization 
that destroys the reputation of the organization [5]. Implementing 
controls and management of data without understanding the 
regulatory and business processes can result in the questionable 
validity of data and may lead to regulatory action. DI is the map of 
maintaining and ensuring the accuracy and consistency of data over its 
lifecycle [6]. Good data storage and record management are vital 
elements of the pharmaceutical quality system. DI refers to 
maintaining and assuring the accuracy and consistency of data over its 
entire life cycle in compliance with its suitable regulatory 
requirements [7]. Organizations expect that pharmaceutical 
organizations have to hold exact records and every single data will be 
accessible to controllers [8]. There are many chances of getting 
corrupted results if there is no proper measures are taken to ensure 
the safety of data. Errors of DI generally arise from human error, 
uncooperative operating procedures, data transfers, defects in 
software and physical negotiation to devices [9]. DI maintenance is an 
essential part of the industry’s accountability to ensure the safety, 
effectiveness and quality of the drug products. Data integrity is a 
serious part of regulatory compliance [10].  
Errors involved in the DI system were classified in fig. 1. 
  
 
Fig. 1: Lapses in data integrity [11] 
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Common data integrity issues 
1. Personnel 
• Personnel qualification  
• Unqualified persons performing critical tasks 
• Inadequate training  
• No demonstration of competency 
• Using improper techniques 
• Inexperienced reviewers 
• Differences between the site contract labs personnel and systems 
• Not enough qualified personnel  
• Active fraud/falsification [12] 
2. Task preparation and execution 
• Unapproved suppliers  
• System/equipment 
• Not calibrated/validated-accuracy and reliability issues 
• Lack of appropriate access controls  
• Overwrite/delete information [13] 
3. Materials 
• Unlabeled samples  
• Processing equipment 
• Unapproved/unverified materials used [14] 
4. Procedures 
• Not thorough enough, leading to variability in performance 
• Missing equipment for data recording 
• Missing data capture [15] 
5. Data collection (Capture/Interpretation/Review) 
• Lack of handling with the deviations tends to fail to record, 
report, investigate or covering up out of specifications (including 
discarding/not documenting failing results) 
• No proper documentation and compilation 
• Inadequate investigations, including a failure to identify root cause  
• Use of un-validated analytical methods 
• Inaccuracies between data systems and specification documents 
[16] 
6. Handling issues 
• Personnel overloaded and cutting corners 
• Documenting changes to approved records without re-approval  
• Failure to follow procedures 
• Lack of verification 
• Mislabeling/not labeling samples  
• Not completing documentation  
• Running trial samples [17] 
7. Data management and archiving 
• Ability to edit data/delete methods  
• Lack of backups/protection of records from loss 
• Failure to retain raw data/complete data as generated 
• Incomplete files/records of data acquired 
• No backup or backups that overwritten earlier data 
• Hybrid systems of both paper/electronic record [18] 
Consequences of data integrity noncompliance 
 Loss of trust 
 Recalls 
 Warning letter/483 observations 
 Import alert/injunction  
 Seizure 
 Non-compliance report 
 Loss of job/loss of business [19] 
Elements of data integrity 
The regulated bodies and industries followed a term called ALCOA 
(Attributable, Legible, Contemporaneous, Original and Accurate) a 
USFDA guidance since 1990, for ensuring data integrity and which is 
a key to handling Good Documentation Practice (GDP) [20]. 
 
Table 1: Required elements for ensuring data integrity 
Elements Abbreviation Explanation Comments 
A Attributable Action that who performed and when? If anyone was changed the record, 
who did it and why? 
Who did it?  
L Legible Recorded data must be permanent, readable and durable medium  Can you read it?  
C Contemporaneous Date and time should be affixed whenever the recorded data was performed Was it done in real-time? 
O Original Is the obtained results are original data? Is it original or true copy? 
A Accurate Without documents amendments no editing/modification to be done Is it accurate data?  
 
Example for attributable 
• During an approval work out, test results ought to be initiated and 
dated by the individual who run the test. 
• Adjustment of a set point on a procedure or checking framework 
ought to be made by an approved client and the details of the 
modifications signed in a review trail [21].  
Note: It is imperative to guarantee a mark log is kept up to recognize 
the marks, initials or potentially assumed names of individuals 
finishing paper records. 
Example for legible 
• The use of permanent ink is recommended when finishing the 
records. 
• During a correction process to a record, a single line is always 
preferable to strike out the old record. This procedure ensures the 
record is still legible [22]. 
Note: Should be readable and permanent 
Example for contemporaneous 
• Electronically performed data, ought to make some date/time 
stamp joined to the record.  
• Ensure electronic frameworks that log information has their 
framework and in synchronized format [24]. 
Note: Data should never be backdated, documented at the time of 
activity 
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Fig. 2: Legible criteria [23] 
 
Example for original 
• Ensure approved test results are recorded on the endorsed 
convention. The recording brings about a note pad for translation 
later that can present blunders.  
• If unique information is written by hand and should be put away 
electronically, guarantee a genuine duplicate is created, the 
duplicate is confirmed for fulfilment and afterward relocated into 
the electronic framework [25]. 
Note: Reliable written printout and certified data 
Example for accurate 
• Use an observer verify for basic record assortment to affirm the 
exactness of the information.  
• Consider how to catch information electronically and check its 
precision. Incorporate precision checks with the plan of the 
electronic framework.  
• Place confirmation on manual information passage, for instance, 
temperature results must be entered inside a pre-defined scope of 0-
100 °C [26]. 
Note: Should complies with actual value and error-free 
USFDA prohibits the following 
• Recording of the data on pieces of paper 
• Storing the data in temporary memory 
• Sampling and testing to achieve a specific result or to overcome 
an unacceptable result as this is not as per the cGMP standards 
• Actual samples to be used to perform system suitability (system 
suitability tests should be done by using written procedures and data 
should be recorded for scientific justification for exclusion) [27]. 
Minimum data integrity requirements  
• Data should be secure from alteration, accidental erasures or loss 
• Backup data should be exact and complete 
• Data should be stored to prevent loss 
• Performed tasks should be documented at the time itself and 
controlled laboratory practices to be maintained [28] 
• The records should be retained as original records and true copies 
• FDA requires data to record complete information, a complete 
record of all data from all the tests performed and no test or data 
should be failed to record [29]. 
Why DI issues happen (Root causes)?  
Shortage of manpower 
Shortage of staff and unnecessary work weight can prompt off base 
and inadequate documentation [30]. 
Quantity over quality 
Employees might be compelled to bargain the adequate quality 
levels to meet creation targets or dispatch courses of events [31]. 
Lack of awareness 
Often, representatives are not prepared or insufficiently prepared to 
understand GMPs. This makes workers consider exercises as a task 
as opposed to understanding their significance by considering GMP 
[32]. 
Effectiveness of training 
While the organization may procure the best worldwide mentors, 
representatives referenced that there were language and highlight 
obstructions, which kept the workers from understanding the 
substance, in this manner making the preparation repetitive [33]. 
Preventing data integrity issues 
Information respectability disappointments have prompted 
organizations losing their licenses, consent orders, cautioning 
letters, import alarms, summon of the application uprightness 
arrangement, terrible exposure when issues become newsworthy 
and more. Assessing at any rate the components introduced in these 
5 significant regions in the process will help recognize where any 
likely information and honesty issues may exist, just as giving plans 
to upgrades [34]. 
Personnel preparation 
The personnel involving in generating, reviewing and approving 
data must have adequate knowledge and skills to generate GMP 
environment and keep up to the data integrity expectations, which 
includes:  
• GMP and 21 CFR Part 11 expectations  
• Change control and validation  
• Good documentation practices 
• Root cause analysis, deviations and investigations 
• Data integration and their guidance documents [35] 
Procedures 
One should ensure that the procedure that, 
• Accurately defines the validated process 
• It is performed in clear and unambiguous language  
• To assure proper execution accurately and constantly by all the 
personnel involved in performing the task [36] 
Equipment/System 
The key elements that guarantee the accuracy and control of 
equipment and systems should be verified, which includes:  
• Equipment must be validated, test strategies, information 
computation/data move systems to guarantee accuracy and right 
execution preceding use 
• The operating systems should be updated from the existing one 
• There should be limited access for the data [37] 
Being proactive 
Being proactive in detecting the potential data integrity issues and 
upholds the civilizing elements supports data integrity in the 
organization. Frequent audits on data integrity should be performed 
and issues in potential or questionable practices should be identified 
[38]. 
Recommendations 
Based on the detailed study of various aspects of DI issues, 
regulatory guidelines, expectations and learning from various 
regulatory inspections/warning letters, the below following are the 
recommendations to prevent and proactively avoid DI issues to 
safeguard the company’s image and reputation for long-lasting, 
sustainable business [39]. Recommendations were determined 
below:  
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• Organizations should focus on long term sustainability instead of 
short term gains 
• Focus on systems and procedures 
• Focus on QBD-Quality by Design/RFT-Right First Time concepts  
• Focus on better process understanding than traditional trial and 
error approach  
• Engage SME-Subject Matter Experts/third party DI consultants 
• Do not put undue pressure on output/yield improvement, which 
may force the people to indulge in DI issues. 
• Enrich internal audit scrutiny/involve cross-functional experts 
for self-inspections and ensure self-inspections are for the 
improvement 
• Provide required and adequate management support in terms of 
resources 
• Nurture knowledge sharing practices and create an appropriate 
platform and share the learning across the various manufacturing 
sites of the same company 
• Learn from mistakes of self and mistakes of other companies 
• Actively watch the happenings in the industry and keep updating 
the skills and knowledge of the core people 
• Focus on effective training and evaluate to measure the benefit of 
training [40] 
CONCLUSION 
The integrity of data performed by any pharmaceutical organization 
is a topmost factor for trustworthiness. The finding of a solitary 
example where information respectability is undermined throws a 
shadow over the entire of the information produced. Discovering the 
occurrence of adulteration brings up the reason for more number of 
cases for such non-compliance on guidelines. Therefore ensuring 
data integrity is a major importance to any pharmaceutical 
organization as the consequences of getting it wrong are very costly 
and it will take a long time to rebuild the trust. Among 
1000+manufacturers in generic pharmaceuticals across the globe, it 
is unclear how many operate in such a way that ensures compliance 
with current and future regulatory agencies in data integrity 
expectations. Getting data integrity right is a huge credit. It needs a 
concentrated, continuous effort to improve and maintain the policies 
involved and discipline culture to avoid regulatory issues. The time, 
hard costs, open door costs and key interruption of fixing a DI 
administrative lack fundamentally exceed the venture of time and 
vitality to make proper DI frameworks and controls. By putting up 
resources into an arrangement of precise, compelling and practical 
consistency will secure productivity and integrity in maintaining the 
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